INC Research Holdings (INCR) Receives Analyst Rating

INC Research Holdings (INCR) : 8 analysts are covering INC Research Holdings (INCR) and their average rating on the stock is 1.88, which is read as a Buy. 4 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. INC Research Holdings (INCR) also receives 1 more Buy recommendations from analysts who believe that the stock will do well going forward. A Zacks Investment Research rank of 1, which recommends a Strong Buy affirms that they expect a large upside in the stock from the current levels. A total of 3 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.

INC Research Holdings (INCR) : Currently there are 5 street experts covering INC Research Holdings (INCR) stock. The most bullish and bearish price target for the stock is $55 and $47 respectively for the short term. The average price target of all the analysts comes to $51.4. The estimated standard deviation from the target is $3.05.


Also, Jefferies maintains its rating on INC Research Holdings (NASDAQ:INCR). The global brokerage major lowers the current price target from $56 per share to $55 per share. Analysts at the Jefferies have a current rating of Buy on the shares. The rating by the firm was issued on August 17, 2016.

INC Research Holdings (NASDAQ:INCR): The stock opened in the green at $43.15 on Thursday, but the bulls found it difficult to push the prices higher. The stock reached a high of $43.15 and a low of $42.215 for the day. The stock did not find buyers even at the lows and closed at $42.94 recording a loss of -0.39%. 633,443 shares exchanged hands during the trading day. The stock had closed at $43.11 in the previous days trading.

INC Research Holdings, Inc. is a global contract research organization (CRO). The Company is focused on Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The Companys segment Clinical Development Services offers a variety of clinical development services, including global studies, clinical monitoring, investigator recruitment, patient recruitment, data management and study reports. The Companys segment Phase I Services focuses on clinical development services for Phase I trials that include scientific exploratory medicine, first-in-human studies through proof-of-concept stages and support for Phase I studies in established compounds. The Companys segment Global Consulting provides consulting services regarding clinical trial regulatory affairs, regulatory consulting services, quality assurance audits and pharmacovigilance consulting, non-clinical consulting and medical writing consulting.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.